Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MTFBW - Motif Bio PLC Warrant 2016-01.11.21 on Motif Bio Sp ADS

Previous close
0.0035
0   0%

Share volume: 0
Last Updated: Mon 16 Dec 2019 06:00:00 AM CET
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
$0.00
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
59%
Profitability 75%
Dept financing 25%
Liquidity 0%
Performance 65%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.00
P/E Ratio 
N/A
DAY RANGE
$0.00 - $0.00
EPS 
$0.00
52 WEEK RANGE
$1.00 - $4.60
52 WEEK CHANGE
-$38.64
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,141
AVERAGE 30 VOLUME 
$805
Company detail
CEO: Graham George Lumsden
Region: US
Website: https://www.motifbio.com/
Employees: 0
IPO year: -
Issue type:
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ.

Recent news